International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study

Trial Profile

International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Iniparib (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Irinotecan; Paclitaxel; Topotecan
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 03 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 21 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
    • 21 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top